NANOBIOTIX Positive Phase 1 on JNJ-1900 (NBTXR3) Combo in Primary Cutaneous Melanoma

Nanobiotix (NASDAQ: NBTX) has announced promising new results from a Phase 1 study of JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors for treating primary cutaneous melanoma resistant to anti-PD-1. The study showed a 47.4% objective response rate and 78.9% disease control rate in all lesions per RECIST 1.1.

Key findings include a median Overall Survival of 14.6 months and establishment of the recommended phase 2 dose at 33% of gross tumor volume. The treatment demonstrated a favorable safety profile, with only 5 patients experiencing treatment-related adverse events. Notably, in JNJ-1900 injected & irradiated tumors, researchers observed a 100% disease control rate.

https://www.stocktitan.net/news/NBTX/nanobiotix-announces-new-results-from-a-phase-1-study-evaluating-jnj-ls02fvt763cy.html